AI for Increasing Reporting of Fatty Liver to Promote Early Detection

Nanox.AI’s unique and pioneering algorithm highlights liver density measurements using abdominal and chest CTs. Low liver density is suggestive of fatty liver disease.

Discover the Need for
Advanced Liver Care

The global prevalence of MASLD
The global prevalence of MASLD is 25%
and it is considered a “silent” global pandemic
Prolonged high fat levels in t
Prolonged high fat levels in the liver can lead to fibrosis or MASH,
which can progress to cirrhosis. The mortality rate is 7.9% within seven years.
Early detection of liver di
Early detection of liver disease can help improve patient outcomes
and reduce its complications and healthcare costs
MASLD is associated with annua
MASLD is associated with annual direct medical costs of ~$103 billion 
$1613 per patient

Proven Value

In a study published in AJR, the Nanox.AI liver solution demonstrated enhanced diagnostic accuracy and automation efficiency

In a study published in AJR, t

FLD and Cardiovascular Risk 

There is a strong association between NAFLD and atherosclerotic heart disease, heart failure, and arrhythmias, particularly atrial fibrillation

FLD and Cardiovascular Risk

Want to Learn More?

Get Your Demo

AI Solutions for Better Outcomes 

Improving Clinical Outcome

Improving Clinical Outcome

The AI-driven analysis enhances clinical outcomes by automatically measuring liver attenuation on contrast and non-contrast chest and abdominal CT scans.

Generating Value

Generating Value

Nanox.AI measures liver attenuation (HU), highlights results that fall outside the reference range, and visualizes the measurement location.

Seamless Integration

Seamless Integration

Seamless integration with existing Picture Archiving and Communication Systems (PACS) enables timely and appropriate preventive care.

Adding Clinical Value to Radiology Reports

The AI Liver solution helps bridge the divide between radiology and gastroenterology, two medical specialties that often use different terms and descriptions to assess imaging data by adding clinical value as numerical scoring to the radiology report

Do More With AI

Join us on Nanox.AI’s journey to discover how our innovative technology can elevate your practice and drive healthcare standards to new heights.

Exploring Insights and Innovations

Explore leading articles in the field of medical imaging, featuring cutting-edge research, breakthrough technologies, and in-depth analyses of the future of medicine. Read more and stay updated with the latest knowledge and development.

Article
Nanox.AI

Guide de pratique de l’AASLD sur l’évaluation clinique et la prise en charge de la stéatose hépatique non alcoolique

Ce nouveau document d’orientation de l’AASLD reflète de nombreuses avancées dans le domaine pertinentes pour tout praticien prenant en charge des patients atteints de NAFLD et met l’accent sur les avancées en matière de stratification des risques non invasive et de traitement.

Poursuivre votre lecture Clock 15 Temps de lecture
Article
Nanox.AI

Détection d’une stéatose hépatique modérée sur un scanner de la veine porte avec injection de produit de contraste : évaluation à l’aide d’un outil automatisé d’intelligence artificielle

La TDM avant contraste est un moyen établi d’évaluation de la stéatose hépatique ; la TDM après contraste a toujours été limitée à cette fin.

Poursuivre votre lecture Clock 10 Temps de lecture
Article
Nanox.AI

Stéatose hépatique non alcoolique, insuffisance cardiaque et mortalité à long terme : perspectives de l’enquête nationale sur la santé et la nutrition

Évaluer l’association entre la stéatose hépatique non alcoolique (NAFLD), l’insuffisance cardiaque (IC) et la mortalité toutes causes confondues. La prévalence de la NAFLD et de l’IC augmente en raison de facteurs de risque communs.

Poursuivre votre lecture
Explore More
Rejoignez l’avant-garde de la technologie
Contactez-nous

Vos informations seront traitées comme détaillé dans notre politique de confidentialité